Education, Conference Coverage and Articles
Dr Clarissa Melo Czekster is a rising star in the field of enzymology and bacterial pathogenesis. In this Q&A, she reflects on her early inspirations, key mentors, and the molecular curiosity that drives her work in infectious diseases. From childhood experiments to developing novel antibiofilm tools, her career blends biochemical precision with a passion for collaborative science.
"Even with intensive support, short-cycle therapy did not match the effectiveness of daily treatment in adolescents." - Dr Adeodata R. Kekitiinwa Short-cycle therapy (SCT) has previously shown promise in maintaining viral suppression among young people living with HIV. In ...
A resident of northern Arizona, USA, has died after contracting pneumonic plague, a rare but highly serious form of the disease caused by the bacterium Yersinia pestis, according to a statement from the Coconino County Health and Human Services (CCHHS). This is the first confirmed plague-related fatality in the county in several years and has prompted increased public health monitoring and community awareness efforts.
Despite the availability of curative therapies, hepatitis C virus (HCV) remains a global health challenge.
In this Q&A, you will learn:
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
We are delighted to welcome Dr Dariusz Hareza to the touchINFECTIOUS DISEASES Editorial Board. Dr Hareza is an Assistant Professor of Medicine (Infectious Diseases) at Northwestern University Feinberg School of Medicine, Chicago, IL, USA. He brings to the board a ...
The US Food and Drug Administration (FDA) has expanded the indication of the pangenotypic direct-acting antiviral (DAA) combination, glecaprevir/pibrentasvir (Mavyret®; AbbVie Inc., North Chicago, IL, USA), to include the treatment of acute hepatitis C virus (HCV) infection in adults ...
The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...
We are delighted to announce that Dr. Ikechukwu Benjamin Moses has joined the touchINFECTIOUS DISEASES Editorial Board! “I strongly believe that this platform will greatly contribute in promoting science to a broader audience with strong societal impact.” Dr Moses brings ...
The ESCMID Global Congress 2025 brought together world-leading researchers and clinicians to present practice-changing updates in infectious disease management. This article distils five critical insights from interviews and landmark trial results, covering innovations in antimicrobial therapy, fungal infections, resistance surveillance and ...
The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.
Dr. Ikechukwu B. Moses, winner of the ESCMID Global 2025 Emerging Young Investigator Award, explores antimicrobial resistance through a One Health lens. His work spans zoonotic pathogen transmission, bacteriophage therapy, and AI-driven genomic research, aiming to reduce antibiotic reliance and translate lab-based innovations into scalable, real-world clinical and veterinary solutions.
Dr Dariusz Hareza reflects on ESCMID Global 2025, highlighting its international scope, informal collaboration, and key themes in antimicrobial resistance. He discusses impactful sessions on global surveillance, Kazakhstan’s primary care initiatives, and novel approaches like CRISPR and AI, all pointing toward an innovative and integrated future in infectious diseases.
The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.